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Abstract
Background Low-dose lansoprazole has not been inten-
sively evaluated for its efﬁcacy in the prevention of
recurrent gastric or duodenal ulcers in patients receiving
long-term non-steroidal anti-inﬂammatory drug (NSAID)
therapy for pain relief in such diseases as rheumatoid
arthritis, osteoarthritis, and low back pain.
Methods This multi-center, prospective, double-blind,
randomized, active-controlled study involving 99 sites in
Japan was designed to compare the efﬁcacy of lansoprazole
(15 mg daily) with gefarnate (50 mg twice daily). Patients
with a history of gastric or duodenal ulcers who required
long-term NSAID therapy were randomized to receive
lansoprazole 15 mg daily (n = 185) or gefarnate 50 mg
twice daily (n = 181) and followed up for 12 months or
longer prospectively.
Results The cumulative incidence of gastric or duodenal
ulcer at days 91, 181, and 361 from the start of the study
was calculated by the Kaplan–Meier method as 3.3, 5.9,
and 12.7%, respectively, in the lansoprazole group versus
18.7, 28.5, and 36.9%, respectively, in the gefarnate group.
The risk for ulcer development was signiﬁcantly (log-rank
test, P\0.0001) lower in the lansoprazole group than in
the gefarnate group, with the hazard ratio being 0.2510
(95% CI 0.1400–0.4499). A long-term follow-up study
For the Lansoprazole Ulcer Prevention Study Group (NSAID
Therapy).
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DOI 10.1007/s00535-012-0541-zshowed an acceptable safety proﬁle for low-dose lansop-
razole therapy, with diarrhea as the most frequent adverse
event.
Conclusion Lansoprazole was superior to gefarnate in
reducing the risk of gastric or duodenal ulcer recurrence in
patients with a deﬁnite history of gastric or duodenal ulcers
who required long-term NSAID therapy.
Keywords Non-steroidal anti-inﬂammatory drugs 
Rheumatoid arthritis  Osteoarthritis  Gastric or duodenal
ulcers  Prevention  Lansoprazole  Active-controlled trial
Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) continue
to be in widespread use due to an increase in the prevalence
of diseases in the aging population that respond to NSAIDs
and due to their crucial role as effective antipyretic anal-
gesics in a wide spectrum of conditions and diseases
ranging from a common cold to rheumatoid arthritis (RA).
However, they are known to disrupt the mucosal resistance
to gastric acid through mechanisms including suppression
of prostaglandin production in the gastric mucosa, and are
thus associated with adverse events such as gastric or
duodenal ulcers.
In a meta-analysis published in 1991 [1], the overall
odds ratio (OR) of the risk for adverse gastrointestinal (GI)
events in NSAID users was shown to be 2.74 compared to
non-NSAID users based on data from 16 studies, with this
relative risk markedly increased among high-risk patients,
i.e., those with additional risk factors such as an age greater
than 60 years, a previous history of GI events, and con-
comitant corticosteroid use [1–3].
Various guidelines recommend discontinuation of
NSAID therapy at the onset of GI events, such as GI
bleeding [4]. However, NSAID users include patients who
require long-term NSAID therapy, such as those with RA,
and discontinuation of NSAID therapy in these patients is
associated with decreased quality of life due to the return of
pain and inﬂammation. Thus, it is vitally important to
ensure continued prophylaxis of GI adverse effects asso-
ciated with NSAID use in patients requiring long-term
NSAID therapy.
In this context, a number of controlled studies have
reported on the prevention of gastric or duodenal ulcers in
patients during NSAID therapy with misoprostol, proton
pump inhibitors (PPIs), and histamine H2 receptor antag-
onists (H2RAs) [5–11]. Based on the evidence obtained to
date, a clinical expert consensus statement [4] recommends
PPIs as preferred agents for the prophylaxis of NSAID-
associated GI injury. However, to date, low-dose lansop-
razole has not been evaluated in a clinical trial for its
prophylactic efﬁcacy in patients with deﬁnitive evidence of
previous ulcer development with/without Helicobacter
pylori (H. pylori) infection, although low-dose or regular-
dose lansoprazole was shown to be effective in preventing
NSAID-induced ulcers in patients without H. pylori
infection [7, 9].
This study aimed to examine the preventive effect of
low-dose lansoprazole (15 mg daily) against the recurrence
of gastric or duodenal ulcers associated with long-term
NSAID therapy excluding low-dose aspirin (LDA) in
patients with deﬁnitive evidence of previous ulcer devel-
opment, which is counted among distinct risk factors for GI
bleeding. Ulcer recurrence was deﬁned as endoscopically
conﬁrmed ulcers based on the predeﬁned criteria and
reconﬁrmed by an independent panel of endoscopists. The
occurrences of gastric or duodenal bleeding requiring or
not requiring hospitalization were also evaluated.
Methods
Design overview
The study protocol was approved by the ethics committee
of each participating institution, and all patients gave
written informed consent to participate in the study.
The Independent Data Monitoring Committee planned
an interim analysis in advance to investigate whether or not
to continue the study in light of interim efﬁcacy and safety
ﬁndings, based on the predeﬁned criteria. However, the
Independent Data Monitoring Committee recommended
discontinuing this trial based on the ﬁnal results of a
companion trial of lansoprazole for prevention of gastric or
duodenal ulcers associated with LDA therapy, which
showed strong efﬁcacy of low-dose lansoprazole [12].
After the Committee made the decision to discontinue the
double-blind trial, the patients in the 47 healthcare insti-
tutions were invited to move on to the follow-up study with
open-label lansoprazole treatment lasting up to 6 months.
This trial was registered with ClinicalTrials.gov (number
NCT00787254).
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123Setting and participants
Patients were enrolled in the study if they met the fol-
lowing criteria: those who were taking an NSAID when
they gave informed consent, and who required long-term
NSAID therapy (LDA excluded) after the start of the study
(day 1) with the investigational drug and those in whom a
history of gastric and/or duodenal ulcer was conﬁrmed by
endoscopy, i.e., those who were conﬁrmed to have an ulcer
scar either on day 1 or through an endoscopic examination
(e.g., photographs, ﬁlms) performed prior to day 1.
Patients were excluded if they had an open gastric or
duodenal ulcer or an active upper GI hemorrhage con-
ﬁrmed by endoscopy on day 1, aspirin-induced asthma or
hypersensitivity to NSAIDs including aspirin or a history
of hypersensitivity, a history of surgery or a planned
operation that could affect gastric secretion (e.g., upper GI
tract resection, vagotomy), clinically signiﬁcant liver or
kidney disorders [including liver tests demonstrating AST
(GOT)/ALT (GPT) values 2.5 times or higher than the
upper limit of normal or creatinine levels 2.0 times or
higher than the upper limit of normal], severe cardiac
dysfunction, hypertension, or hematological diseases, and
active cancers.
All patients conﬁrmed to be eligible at each trial site
were reassessed for their eligibility, based on endoscopic
images either on ﬁlms or data submitted after randomiza-
tion, by an independent panel of expert endoscopists.
Randomization and intervention
Patients who met the inclusion criteria were randomly
assigned to either of the following two treatment groups: a
group receiving the investigational drug (lansoprazole
15 mg orally given once daily) and cytoprotective anti-
ulcer agent gefarnate placebos (twice daily) or a group
receiving gefarnate (50 mg orally given twice daily) and
the lansoprazole placebo (once daily), in combination with
an NSAID at the doses indicated in their package inserts
for a duration of 6 months or longer (up to 24 months).
Acetaminophen and celecoxib, which are reported to be
less associated with GI injury, were excluded, along with
LDA, which was studied in a separate trial [12]. Lansop-
razole and gefarnate placebos were used to ensure that all
patients followed the same regimen and that blinding was
maintained. Treatment groups were assigned by using
computer-generated random sequence numbers. Patients
were randomly assigned by investigators to receive lan-
soprazole or gefarnate in a 1:1 ratio according to the unique
sequential numbers for the study drugs, which were pre-
assigned to each study site before the start of the treatment.
When the onset of ulcer was diagnosed endoscopically or
the NSAID was changed to a different drug, the subjects
were excluded from the study at that time point. To mon-
itor the status of subject compliance to AG-1749 or
gefarnate, the dosage (number of capsules) used for each was
calculated and compared to that dispensed for each subject.
The use of any medication that could affect the onset of
gastric or duodenal ulcer, including corticosteroids, anti-
platelet agents and anticoagulants, was prohibited during
the course of the study.
Outcomes and measurements
The primary endpoint was the recurrence of gastric or
duodenal ulcers, deﬁned as open ulcers (either active- or
healing-stage) associated with a mucosal defect with
whitish exudates measuring 3 mm or greater. All ulcers
conﬁrmed on endoscopy and reported from each study site
were reconﬁrmed by the independent expert panel based on
submitted ﬁlms. The secondary endpoints were the devel-
opment of gastric and/or duodenal hemorrhagic lesions as
observed with endoscopy with or without hospital admis-
sion, treatment discontinuations due to lack of efﬁcacy,
gastric and/or duodenal mucosal damage as assessed with a
modiﬁed Lanza score [13], and GI symptoms.
Follow-up procedures
Endoscopy was scheduled every 12 weeks until 6 months
of treatment and every 24 weeks after 6 months. Non-
scheduled endoscopies were also performed if patients
were suspected of having symptoms associated with ulcers
or signs and symptoms indicative of GI bleeding.
Every 4 weeks, blood pressure was measured, clinical
laboratory tests (chemistry, hematology, and urinalysis)
were performed, compliance checks (returned tablet
counts) conducted, and patients asked about any adverse
effects they experienced. All patients were scheduled to
receive the study treatments in a double-blind fashion until
6 months after the start of the study in the last enrollment.
After the termination of the double-blind trial, patients in
the 47 study sites were invited to participate in the follow-
up study, in which all patients were treated once daily with
lansoprazole 15 mg. If the onset of ulcer was conﬁrmed on
endoscopy in a patient, the patient discontinued his/her
medication and antiulcer treatment such as full-dose PPI
therapy was offered for ulcer healing.
Statistical analysis
In an earlier study by Graham et al. [7], the recurrence rate
was shown to be 20% in the lansoprazole group versus 49%
in the placebo group, leading to a reduction of about 60%
in the risk of ulcer recurrence in patients receiving lan-
soprazole. Also, a recent meta-analysis [14] suggested that
542 J Gastroenterol (2012) 47:540–552
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effects in Asians than in Caucasians. Thus, using a con-
servative estimate, a 60% reduction in the risk of ulcer
recurrence was assumed in Japanese patients receiving
lansoprazole, equivalent to that in Caucasians, with an
estimated annual ulcer recurrence of 8% (20% 9 0.4 =
8%). On the other hand, to date, no data are available for
prevention of ulcer recurrence during NSAID therapy with
the reference drug gefarnate. In this respect, an earlier
study by Agrawal et al. [15] evaluating misoprostol versus
sucralfate (a close counterpart to gefarnate) given 3 months
in patients with a history of NSAID-associated ulcer
reported a recurrence rate of 16% in the sucralfate-treated
group, from which, however, no deﬁnitive conclusions can
be drawn regarding the prophylactic effect of sucralfate
due to lack of a placebo-controlled arm in the study.
Assuming that sucralfate (or gefarnate) should be signiﬁ-
cantly less potent than misoprostol or lansoprazole in
prophylactic efﬁcacy against ulcer recurrence, we esti-
mated gefarnate in this study would reduce the rate of ulcer
recurrence by 15% compared to placebo, leading to an
annual ulcer recurrence of 17% (20% 9 0.85).
This estimation meant that the hazard ratio (HR) of the
lansoprazole-treated group relative to the gefarnate-treated
group was 0.4475 under an exponential assumption on
event distributions. The study required a total of 66 ulcer
events (endpoints) for the two treatment groups to ensure a
statistical power of 90% using a log-rank test with a two-
sided alpha of 5%. To observe 66 events, the study required
enrollment of 301 patients for each treatment group at
randomization for a total of 602 patients, assuming a mean
follow-up duration of 6 months and a 6-month dropout rate
of 15%.
One interim analysis was planned in advance for the
Independent Data Monitoring Committee to perform when
half of the required number of ulcer events was observed.
The O’Brien-Fleming boundary based on the information
fraction of 0.5 was employed for an overall signiﬁcance
level of a = 0.05. To avoid unnecessary trial hazard to the
patients assigned to either treatment, the investigators
planned to discontinue the double-blind trial if the differ-
ence in the primary endpoint was shown to be signiﬁcant in
the interim analysis. However, this trial was prematurely
terminated without doing the interim analysis based on the
decision of the Independent Data Monitoring Committee.
The cumulative incidences of the primary and secondary
endpoints were estimated by using the Kaplan–Meier
method and compared between the treatment groups by
using the log-rank test. For event-free cases, the event
times were censored either at the point of the last endos-
copy performed or at the point of early withdrawal. Mul-
tivariate Cox regression analyses were also performed to
adjust for the possible effect of baseline variables on event
times. The ﬁnal analyses were conducted for the full
analysis set (FAS), deﬁned as all patients who were ran-
domized and received one or more doses of the study
medication. In the survival analysis, the patients at risk
were deﬁned as all event-free FAS patients who had at least
one post-randomization assessment with endoscopy.
Differences in subjects demographics (Table 1) and
adverse events (Table 5) between the lansoprazole and
gefarnate groups were tested for signiﬁcance by using the
v
2 test, except mean age, mean duration of prior NSAID
and compliance rate (all in Table 1) were tested by t test.
Analyses were conducted by using SAS software (ver-
sion 9.1.3; SAS Institute Inc., Cary, NC, USA). One and
the same statistician (SM) had full access to all the trial
data and conducted statistical analyses independently of the
sponsoring company.
Detection of infection and CYP2C19 polymorphisms
H. pylori infection status was determined for each patient
by using an E-plate Eiken H. pylori antibody assay kit
(Eiken chemical Co., Ltd.) at a central laboratory. Patients
were judged to be ‘‘negative’’ if the antibody level was
\10 U/ml. For CYP 2C19 pharmacogenomics analysis,
the whole blood samples were collected from patients who
gave separate informed consent for CYP2C19 polymor-
phism analysis. Polymorphisms and types of CYP2C19
metabolization (extensive or poor) were determined for all
consenting subjects by the PCR–RFLP method or ﬂuores-
cent correlation spectroscopy [16] at a central laboratory.
Role of the funding source
Takeda Pharmaceutical Company and its contractor pro-
vided all ﬁnancial and material support for the study
design, data collection, data analysis, data interpretation,
and preparation and review of manuscripts. The Sponsor
was also responsible for consultations with the authors and
the members of this study group about the study design and
monitoring of the study. The principal investigator (KS)
was responsible for the study design as well as for prepa-
ration of the manuscript. All co-authors reviewed the
manuscript and necessary revisions were made to accom-
modate their suggestions and opinions.
Results
Study patients
This prospective, double-blind, randomized, active-con-
trolled trial with an open-label 6-month follow-up study
was conducted at a total of 99 healthcare institutions in
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practice and the Declaration of Helsinki, from April 2007
to October 2009 (inclusive of the follow-up study). Based
on the results of the preceding LDA study [12], the Inde-
pendent Data Monitoring Committee made the decision to
terminate the double-blind part of the study early. The
results presented here are based on the completed and
analyzed ﬁnal data.
Figure 1 shows the ﬂow diagram in this trial. Of the 916
patients enrolled, 366 patients were randomized, while the
remaining 550 patients were excluded primarily because
they were not conﬁrmed to meet the inclusion criteria. Of
the 366 patients randomized, 185 were assigned to receive
lansoprazole and 181 to receive gefarnate. Of the 185
patients assigned to lansoprazole, two patients were not
given the study medication because one patient voluntarily
discontinued the study medication and the other was lost to
follow-up after the initial prescription.
The FAS population comprised a total of 364 patients,
with 183 and 181 patients in the lansoprazole group and the
gefarnate group, respectively. The numbers of withdrawals
were similar between the treatment groups, with 76 (41.1%
of 185 randomized patients) in the lansoprazole group and
82 (45.3%) in the gefarnate group. The most frequent
reasons for withdrawal were protocol deviations (including
failure to take the medication), which occurred in 28
(36.8%) patients in the lansoprazole group and in 23
(28.0%) patients in the gefarnate group, followed by
adverse reactions and consent withdrawals in 24 (31.6%)
and 16 (21.1%) patients, respectively, in the lansoprazole
group, and in 23 (28.0%) and 11 (13.4%) patients,
respectively, in the gefarnate group. Additionally, four
patients in the lansoprazole group and 15 patients in the
gefarnate group withdrew due to lack of efﬁcacy or sus-
pected ulcer-related symptoms/diagnoses. The median
duration of follow-up was 6.6 months (range 0.0–22.2) for
the lansoprazole group and 3.8 months (range 0.1–19.8) for
the gefarnate group, with the follow-up being 2.8 months
longer in the lansoprazole group, with many patients dis-
continuing gefarnate due to recurrence of gastric or duo-
denal ulcer. Compliance with the study medication and
NSAID therapy was similarly high in the two treatment
groups. There was no difference between the treatment
groups in the frequency distribution of baseline variables
(Table 1).
Efﬁcacy
In the FAS population, the cumulative number of gastric or
duodenal ulcer recurrences, i.e., primary endpoint, at the
end of the study was 15/183 (8.2%) in the lansoprazole
group and 46/181 (25.4%) in the gefarnate group (Table 2).
The cumulative recurrences at days 91, 181, and 361 from
the start of the study were estimated as 3.3% (95% CI
0.45–6.18), 5.9% (95% CI 1.87–9.83), and 12.7% (95% CI
5.85–19.59), respectively, for the lansoprazole group,
compared to 18.7% (95% CI 12.27–25.07), 28.5% (95% CI
20.69–36.39), and 36.9% (95% CI 27.51–46.35), respec-
tively, for the gefarnate group (Fig. 2). The HR of the
Table 1 Demographic and baseline characteristics of Japanese
patients randomized to treatment
Lansoprazole
(n = 185)
Gefarnate
(n = 181)
P value
Mean age (SD, years) 62.8 (11.72) 63.7 (11.05) 0.4501
Sex 0.7811
Male 73 (39.5) 74 (40.9)
Female 112 (60.5) 107 (59.1)
Current smoker 55 (29.7) 64 (35.4) 0.2504
Alcohol consumption 63 (34.1) 67 (37.0) 0.5538
Mean duration (SD) of
prior NSAID (months)
a
21.8 (14.87) 22.1 (14.37) 0.8445
Status of concomitant
NSAID use
0.7018
Loxoprofen sodium
hydrate
72 (38.9) 76 (42.0)
Meloxicam 30 (16.2) 30 (16.6)
Diclofenac sodium 22 (11.9) 27 (14.9)
Etodolac 24 (13.0) 20 (11.0)
Others 37 (20.0) 28 (15.5)
Underlying disease
b
Rheumatoid arthritis 75 (40.5) 76 (42.0) 0.4174
Osteoarthritis 64 (34.6) 66 (36.5) 0.7087
Low back pain 6 (3.2) 8 (4.4) 0.5574
Others 85 (45.9) 72 (39.8) 0.2333
H. pylori status 0.3966
Positive 93 (50.3) 99 (54.7)
Negative 92 (49.7) 82 (45.3)
CYP2C19 polymorphism 0.5081
PM 32 (17.3) 35 (19.3)
EM 137 (74.1) 125 (69.1)
Mean compliance rate (SD)
Study drug 97.5 (11.1) 97.9 (5.1) 0.6570
NSAID therapy 93.1 (10.4) 93.5 (6.3) 0.6558
Data are presented as numbers (and % of total) except where other-
wise indicated
Unknown in 37 patients for whom consent was not obtained for the
CYP2C19 polymorphism test
PM poor metabolizers, EM extensive metabolizers
a Those who reported taking NSAIDs for[3 years prior to the start
of the study medication were construed as having taken them for
3 years
b Some patients were included in more than one disease category.
‘‘Others’’ include treatments such as lumbar spinal stenosis or inter-
vertebral disc hernia
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0.2510 (95% CI 0.1400–0.4499), which implied a 74.9%
risk reduction, and the difference was highly signiﬁcant
(log-rank test, P\0.0001) (Table 2).
As to the secondary endpoints (Table 2), the risk of
developing gastric/duodenal ulcers or hemorrhagic lesions
in the lansoprazole group was signiﬁcantly lower than that
in the gefarnate group (log-rank test, P\0.0001). Simi-
larly, the risk of having gastric/duodenal ulcers, hemor-
rhagic lesions, or treatment discontinuations due to lack of
efﬁcacy was signiﬁcantly lower in the lansoprazole group
than in the gefarnate group (log-rank test, P\0.0001).
The magnitude of risk reduction in gastric or duodenal
ulcers (primary endpoint) was generally stable for all
subgroups as deﬁned by each baseline variable (Table 3).
The analyses in both H. pylori-positive and -negative
subgroups showed ulcer risk reductions, with a HR of
0.1798 (95% CI 0.0740–0.4369; P\0.0001) and 0.3327
(95% CI 0.1504–0.7361), respectively, in each of the
subgroups in the lansoprazole group as compared to the
gefarnate group. Furthermore, the risk reduction in terms of
HR was estimated as 0.272 (95% CI 0.146–0.504;
P\0.0001 by a Wald test) after adjustment for the base-
line variables, H. pylori status, CYP2C19 polymorphism,
age, sex, smoking, alcohol consumption, and concomitant
use of anticoagulants in a multivariate Cox regression
analysis (Table 4).
We also analyzed sites of recurrent ulcers to examine
whether they recurred in similar sites to the scars observed
at the start of the study. In 26 (42.6%) of these patients,
Fig. 1 Patient disposition in this trial (2010 CONSORT ﬂow diagram). As noted in the manuscript, the study was prematurely terminated for
ethical reasons before accrual of the expected number of patients. GI gastrointestinal
J Gastroenterol (2012) 47:540–552 545
123ulcer recurrence was observed in similar sites to the scars
seen at the start of the study.
GI damage as assessed by a modiﬁed Lanza score [13]
from the start of treatment tended to improve in the lansop-
razolegroupbuttoworseninthegefarnategroup,throughout
the course of treatment, with a signiﬁcant difference seen
between the treatment groups from baseline to 6 months
after the start of treatment (Supplemental Fig. 1a, 1b).
Inthe FAS population,the cumulative numberofpatients
who developed gastric or duodenal hemorrhagic lesions at
the end of the study was two of the 183 patients in the lan-
soprazole group compared to 10 of the 181 patients in the
gefarnate group. The cumulative incidence rate was calcu-
lated by the Kaplan–Meier method (Supplemental Fig. 2),
and the risk of hemorrhage was shown to be signiﬁcantly
lower in the lansoprazole group than in the gefarnate group.
Bleeding ulcers occurred in two patients in the lansoprazole
group and in three in the gefarnate group.
Of the 366 patients randomized to lansoprazole or
gefarnate in this trial, 113 who had received lansoprazole
or gefarnate were included in an open-label follow-up
study to examine outcomes after another 24 weeks of
treatment with lansoprazole, in addition to NSAID therapy.
During this open-label follow-up trial period, ﬁve gastric or
duodenal ulcer recurrences were observed in the continu-
ous lansoprazole group (n = 73) and two recurrences were
observed in the 40 patients who had taken gefarnate in the
double-blind study and were subsequently included in the
open-label study (Supplemental Table 1).
Adverse events
With respect to adverse events observed in the double-
blind study period (Table 5), nasopharyngitis and diarrhea
were C5% more frequent in the lansoprazole group than in
the gefarnate group, while reﬂux esophagitis was noted
C5% more frequently in the gefarnate group. Serious
adverse drug reactions were seen in two patients in the
lansoprazole group (duodenitis and ovarian neoplasm)
Table 2 Effect of lansoprazole on each component of the primary and secondary endpoints
Lansoprazole
a
(n = 183)
Gefarnate
b
(n = 181)
Hazard ratio (95% CI) P value
c
Number at risk at baseline
d 168 162
Primary endpoint
Gastric or duodenal ulcer 15 46 0.2510 (0.1400–0.4499) \0.0001
Secondary endpoints
Gastric/duodenal ulcer and/or hemorrhagic lesion 15 52 0.2196 (0.1235–0.3904) \0.0001
Gastric/duodenal ulcer, hemorrhagic lesion and/or
treatment discontinuation due to lack of efﬁcacy
18 65 0.2158 (0.1279–0.3640) \0.0001
Component
e
Gastric or duodenal ulcer 13 42
Hemorrhagic lesion 0 4
Treatment discontinuation due to lack of efﬁcacy 3 13
Gastric or duodenal ulcer and hemorrhagic lesion 2 4
Hemorrhagic lesion and treatment discontinuation due to lack of efﬁcacy 0 2
a Patients received lansoprazole 15 mg daily
b Patients received gefarnate 50 mg twice daily
c Log-rank test
d The number of patients at risk included all full analysis set patients who received at least one endoscopy assessment post-randomization, and
had no acute-stage or healing-stage gastric or duodenal ulcer as conﬁrmed by the Independent Adjudication Committee
e The ‘component’ section is intended to indicate the components of the endpoints given above and not the endpoints themselves. Hence, the
hazard ratios and P values have not been calculated
Fig. 2 Kaplan–Meier estimates of the cumulative incidence of
gastric or duodenal ulcers in the treatment groups
546 J Gastroenterol (2012) 47:540–552
123versus one in the gefarnate group (cardiac failure). Four
deaths occurred total: two deaths in the lansoprazole group
due to necrotizing pancreatitis and myocardial infarction,
whose causal relationship to lansoprazole was denied, and
two deaths in the gefarnate group due to pancreatic cancer
and cardiac failure. The relationship between gefarnate and
Table 3 Analysis of subgroups as deﬁned by each baseline variable
Baseline
characteristic
Recorded number of patients with gastric or duodenal ulcer Cox regression analysis
Lansoprazole Gefarnate Hazard ratio (95% CI) P value
H. pylori status
Positive 6/81
a 27/87
b 0.1798 (0.0740–0.4369) \0.0001
Negative 9/87
a 19/75
b 0.3327 (0.1504–0.7361) 0.0044
CYP2C19
PM 4/30
c 7/32
d 0.4675 (0.1360–1.6070) 0.2167
EM 10/124
c 30/112
d 0.2408 (0.1176–0.4929) \0.0001
Age (years)
25–64 7/86 20/83 0.2254 (0.0946–0.5370) 0.0002
65–85 8/82 26/79 0.2766 (0.1251–0.6112) 0.0007
Smoking status
Yes 5/48 19/60 0.2262 (0.0840–0.6088) 0.0014
No 10/120 27/102 0.2649 (0.1281–0.5481) 0.0001
Alcohol consumption
Yes 5/57 16/63 0.2873 (0.1048–0.7877) 0.0096
No 10/111 30/99 0.2377 (0.1161–0.4866) \0.0001
Underlying disease
Rheumatoid arthritis
Yes 7/68 21/67 0.2342 (0.0993–0.5522) 0.0003
No 8/100 25/95 0.2664 (0.1201–0.5913) 0.0005
Osteoarthritis
Yes 4/59 17/58 0.1904 (0.0640–0.5665) 0.0009
No 11/109 29/104 0.2860 (0.1426–0.5734) 0.0002
Data are presented as numbers at risk
At risk: the number of patients at risk included all full analysis set patients who had at least one post-randomization endoscopy assessment, and
had no acute-stage or healing-stage gastric or duodenal ulcer as conﬁrmed by the Independent Adjudication Committee
Results of Cox regression analyses in lansoprazole or gefarnate group, respectively, between each group indicated (H. pylori-positive vs.
-negative and CYP2C19 PM vs. EM); hazard ratio (95% CI) and P value
PM poor metabolizers, EM extensive metabolizers
a H. pylori-positive vs. -negative; 0.6306 (0.2240–1.7750), P = 0.3825
b H. pylori-positive vs. -negative; 1.1418 (0.6338–2.0571), P = 0.6588
c PM vs. EM; 0.6890 (0.2160–2.1977), P = 0.5291
d PM vs. EM; 1.2611 (0.5520–2.8812), P = 0.5821
Table 4 Results of multivariate
Cox regression analysis using
baseline variables
PM poor metabolizers, EM
extensive metabolizers
Baseline characteristics Direct estimation Multivariate analysis
Hazard ratio (95% CI) P value
Treatment group Lansoprazole/gefarnate 0.271 (0.146–0.504) \0.0001
H. pylori status Positive/negative 0.986 (0.565–1.721) 0.9616
CYP2C19 PM/EM 1.031 (0.518–2.054) 0.9308
Age 10 years’ increase 1.189 (0.913–1.548) 0.1987
Sex Male/female 0.978 (0.524–1.827) 0.9455
Smoking status Yes/no 1.5 (0.815–2.758) 0.1925
Alcohol consumption Yes/no 0.774 (0.412–1.457) 0.4277
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123the death from pancreatic cancer was denied, and there was
no deﬁnite causal relationship established between gefar-
nate and the death due to cardiac failure. No deaths
occurred in the follow-up study period.
During the entire study, including the follow-up period,
adverse events leading to treatment discontinuations were
seen in 35 of the 223 patients treated with lansoprazole
(Supplemental Table 2), where diarrhea was the most fre-
quent of all events reported.
Discussion
Risk factors for NSAID ulcer include advanced age [1], a
history of ulcers or GI bleeding [3], and concomitant use of
anticoagulants [4]. It is of note that the present study rep-
resents the ﬁrst to provide evidence for the prophylactic
effect of lansoprazole 15 mg against NSAID-associated
ulcer recurrence in Japanese patients with a deﬁnite history
of ulcer. Pharmacological inhibition of cyclooxygenase
(COX) by NSAIDs is shown to decrease COX-derived
prostaglandin production, suggesting that decreased endog-
enous prostaglandin production in the gastric mucosa may
result in the disruption of mucosal resistance to gastric
acid, thereby inducing the onset of gastric or duodenal ulcers
as adverse events. In this regard, both lansoprazole and
sucralfate, a drug of the same class with gefarnate, are
shown to produce overall increases in duodenal mucosal
turnover and transforming growth factor-alpha (TGF-a)
levels, as well as in epidermal growth factor receptor
(EGF-r) levels [17]. In light of these ﬁndings, therefore, the
greater protection against NSAID-associated ulcer recur-
rence seen with low-dose lansoprazole than with gefarnate
may be accounted for by the potent acid-inhibitory effect of
low-dose lansoprazole.
Given that no drug has been proven to be effective for
prevention of gastric or duodenal ulcer associated with
long-term NSAID therapy in Japan and that it is unethical
to conduct a placebo-controlled trial in patients at high risk
of developing gastric or duodenal ulcers, the current study
was designed to compare the efﬁcacy of lansoprazole
15 mg once daily and gefarnate 50 mg twice daily.
Gefarnate was included as an active-control, since it is a
cytoprotective anti-ulcer agent commonly used in Japan in
reducing the risk for gastric and duodenal ulcers in daily
medical practice. To minimize the risk to the patients
enrolled in this trial, they were strictly assessed by endo-
scopic examination for eligibility. In addition, unlike most
long-term clinical trials conducted to date in a similar
patient population, frequent endoscopic examinations
Table 5 Frequency of adverse
events
Table data are numbers (%) of
patients in whom an event
occurred at least one time
during the trial. Numbers in
brackets for adverse events are
incidence rates in person-years
Adverse events observed in the double-blind
period
Lansoprazole
(n = 183)
Gefarnate
(n = 181)
P value
All adverse events 154 (84.2) [121.2] 125 (69.1) [127.7] 0.0006
Causal relationship to drug not deniable 28 (15.3) [22.0] 28 (15.5) [28.6] 0.9643
Leading to treatment discontinuations 29 (15.8) 23 (12.7) 0.3920
Serious adverse events 29 (15.8) [22.8] 17 (9.4) [17.4] 0.0638
Causal relationship to drug not deniable 2 (1.1) [–] 1 (0.6) [–] 0.5685
Deaths 2 (1.1) 2 (1.1) 0.9918
Adverse events reported in at least 3% of total in each group
Nasopharyngitis 57 (31.1) [44.9] 42 (23.2) [42.9] 0.0769
Diarrhea 19 (10.4) [15.0] – \0.0001
Fall 12 (6.6) [9.4] 10 (5.5) [10.2] 0.6793
Constipation 10 (5.5) [7.9] 10 (5.5) [10.2] 0.9798
Eczema 10 (5.5) [7.9] – 0.0014
Osteoarthritis 8 (4.4) [6.3] 6 (3.3) [6.1] 0.6001
Reﬂux esophagitis – 12 (6.6) [12.3] 0.0003
Hypertension 7 (3.8) [5.5] 8 (4.4) [8.2] 0.7753
Contact dermatitis – 7 (3.9) [7.2] 0.0072
Nausea 6 (3.3) [4.7] – 0.0140
Foot tinea 6 (3.3) [4.7] – 0.0140
Pneumonia 6 (3.3) [4.7] – 0.0140
Back pain 6 (3.3) [4.7] – 0.0140
Elevated blood creatine phosphokinase levels 6 (3.3) [4.7] 8 (4.4) [8.2] 0.5713
Rheumatoid arthritis – 6 (3.3) [6.1] 0.0130
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123(every 3 or 6 months) were scheduled by the protocol to
closely monitor the study subjects to ensure early detection
of ulcer recurrence, similar to the LDA study [12].
As in the LDA study [12], this study also included both
H. pylori-positive and -negative patients without any eradi-
cation therapy, given the relatively high background preva-
lence of H. pylori infection in Japan. There are a number of
reasons that support the rationale for this approach.
First, although H. pylori eradication is generally rec-
ommended in most situations [18–20], trial results reported
to date are not consistent. One study [21] showed H. pylori
eradication was less effective than omeprazole therapy in
preventing recurrent GI bleeding, which was observed in
18.8% of patients in whom H. pylori had been eradicated
versus 4.4% of patients receiving omeprazole therapy after
6 months of treatment. An 8-week, parallel group, pro-
spective study [22] also showed that H. pylori infection
promoted NSAID ulcer healing with either ranitidine
(66%) or lansoprazole (74 and 50% for 15 and 30 mg).
H. pylori eradication reduced the risk of NSAID ulcers
especially in NSAID-naı ¨ve patients with the OR being
0.26, while it did not lead to a signiﬁcant reduction of risk
in those with a history of concurrent NSAID therapy (OR
0.95) [23].
Analyses of both H. pylori-positive and -negative sub-
groups showed ulcer risk reductions associated with study
drug treatment, with these reductions being greater in
H. pylori-positive patients assigned to lansoprazole but not
in H. pylori-positive patients assigned to gefarnate. This
ﬁnding appears to support the usefulness of low-dose lan-
soprazole for preventing gastric or duodenal ulcers asso-
ciated with NSAID therapy in Japan, where the prevalence
of H. pylori infection is high [24]. Additionally, although
more H. pylori-negative patients will need prophylaxis
against NSAID ulcers in Japan, where H. pylori infection
rate is predicted to gradually decrease [25], the study
ﬁndings suggest the usefulness of low-dose lansoprazole in
high-risk patients requiring long-term NSAID therapy,
regardless of H. pylori status.
An analysis of the study data showed that lansoprazole
signiﬁcantly reduced the risk of ulcer recurrences by
almost 75%. Although the recurrence of ulcers observed
with endoscopy was assessed as the primary endpoint in
this study, other clinical endpoints, such as GI bleeding or
patient hospitalization, have also been compared between
the treatment groups, because these true clinical outcomes
are highly relevant in evaluating the drugs for efﬁcacy.
More patients in the gefarnate group developed gastric or
duodenal hemorrhagic lesions and were hospitalized with
serious adverse events leading to gastric or duodenal
bleeding in this study (Supplemental Table 3). Thus,
overall, lansoprazole was superior to gefarnate in all end-
points assessed in the study.
There are studies reporting an increase of some adverse
events such as community-acquired pneumonia (CAP),
diarrhea, and bone fracture with the use of PPIs [26, 27]. Of
the adverse events reported in the double-blind study, those
seen more frequently in the lansoprazole group than in the
gefarnate group were nasopharyngitis and diarrhea, with
none of these being severe. With regard to diarrhea, while a
potential causal relationship with the study medication in
the lansoprazole group was not denied in 4.4% of its
occurrences (8/183 patients), all these events were not
severe or widely different from the incidence and severity
of diarrhea reported earlier with lansoprazole [28]. In the
case of pneumonia, a causal relationship with the study
medication was denied in all patients in this study, and
analyses of long-term use or meta-analyses did not support
the association between PPIs and CAP [26, 28].
This study has several limitations: high dropout rate
leading to differences in duration of treatment with either
study drug among the participants; the study incorporated
the gefarnate group only as a control group but not as a
placebo group, unlike earlier studies [5, 6]; and all statis-
tical analyses were performed on a fewer number of
patients than that pre-speciﬁed before the start of the study,
due to premature termination of the study for ethical rea-
sons before accrual of the expected number of patients. The
estimates of the treatment effect may have been biased by
early termination of the study and the small number of
events observed in the study. A further limitation is that
endoscopic ulcer occurrence, a surrogate endpoint, was
evaluated as the primary endpoint in this study, with the
hard (true) endpoint of hemorrhagic events being addressed
only in terms of the number of patients who developed
these events.
Nevertheless, the authors believe that this study has its
own merits. First, it clearly demonstrated that low-dose
lansoprazole protected against ulcer development associ-
ated with NSAID usage. A double-blind study by Graham
et al. [7] showed an ulcer risk reduction of about 60% in
H. pylori-negative users of NSAIDs including LDA. Similar
to the previous study demonstrating an ulcer risk reduction
of about 90% with low-dose lansoprazole [12], irrespective
of H. pylori status, in LDA users, this study demonstrated a
75% ulcer risk reduction in NSAID users, with both studies
suggesting a higher risk reduction than that reported in the
study by Graham et al. Furthermore, this study suggested
the possibility that low-dose lansoprazole provided more
potent prophylaxis against ulcers in H. pylori-positive
patients than did gefarnate, suggesting that H. pylori pos-
itivity in the study subjects may be among the factors that
accounted for a greater ulcer risk reduction in this study
than in the study by Graham et al. Second, in this study, the
subjects were endoscopically followed up as often as every
3 months to provide rigorous data on endoscopic ulcer
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123development in these patients. Third, a 6-month, long-term
follow-up period was incorporated into the study to eval-
uate the safety and efﬁcacy of low-dose lansoprazole, and
of note, no such study has been conducted by others to
date. Indeed, in the entire study, including the 6-month
follow-up period, the cumulative incidence rate of gastric
or duodenal ulcers was shown to be 14.4 and 19.6% in
patients treated with lansoprazole at days 361 and 631
(36.9 and 50.3% in the gefarnate group in the double-blind
study data), suggesting the efﬁcacy of lansoprazole sus-
tained over a period of 12 months or longer, which is the
longest period reported to date showing the effectiveness
and safety of PPIs to prevent NSAID ulcers in high-risk
patients.
In Japan, where the society is growing increasingly
aged, there will be an increased need for NSAID therapy in
the management of diseases associated with debilitating
pain in the elderly. Therefore, prevention and treatment of
NSAID-induced ulcers continues to be an urgent and
important issue. In this context, lansoprazole appears to
have a major role to play, as it is shown to reduce the risk
of gastroduodenal ulcers in high-risk patients who require
long-term NSAID therapy for pain relief in such diseases
as RA, osteoarthritis, and low back pain, while at the same
time allowing such NSAID therapy to relieve pain and
inﬂammation associated with these debilitating diseases.
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